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Anecdotal and scientific evidence suggests that Cannabis use may be beneficial in
inflammatory bowel disease (IBD) patients. Here, we have investigated the effect of
a standardized Cannabis sativa extract with high content of cannabidiol (CBD), here
named CBD BDS for “CBD botanical drug substance,” on mucosal inflammation and
hypermotility in mouse models of intestinal inflammation. Colitis was induced in mice by
intracolonic administration of dinitrobenzenesulfonic acid (DNBS). Motility was evaluated
in the experimental model of intestinal hypermotility induced by irritant croton oil. CBD
BDS or pure CBD were given - either intraperitoneally or by oral gavage – after the
inflammatory insult (curative protocol). The amounts of CBD in the colon, brain, and liver
after the oral treatments were measured by high-performance liquid chromatography
coupled to ion trap-time of flight mass spectrometry. CBD BDS, both when given
intraperitoneally and by oral gavage, decreased the extent of the damage (as revealed
by the decrease in the colon weight/length ratio and myeloperoxidase activity) in the
DNBS model of colitis. It also reduced intestinal hypermotility (at doses lower than those
required to affect transit in healthy mice) in the croton oil model of intestinal hypermotility.
Under the same experimental conditions, pure CBD did not ameliorate colitis while
it normalized croton oil-induced hypermotility when given intraperitoneally (in a dose-
related fashion) or orally (only at one dose). In conclusion, CBD BDS, given after the
inflammatory insult, attenuates injury and motility in intestinal models of inflammation.
These findings sustain the rationale of combining CBD with other minor Cannabis
constituents and support the clinical development of CBD BDS for IBD treatment.
Keywords: Cannabis sativa, cannabidiol, cannabinoids, inflammatory bowel disease, colitis, intestinal motility
INTRODUCTION
Inflammatory bowel disease (IBD) is a a chronic immunologically mediated disease with growing
incidence and prevalence rates in industrialized countries (Ananthakrishnan, 2015; Taleban et al.,
2015). Effective pharmacotherapies for IBD are not always available and existing drugs may cause
substantial side-effects leading to poor patient adherence. The anecdotal use of marijuana and/or
preparations from Cannabis sativa L. (hemp) in IBD patients has been recently confirmed by
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investigations in humans (Ravikoff Allegretti et al., 2013; Naftali
et al., 2014; Storr et al., 2014; Izzo et al., 2015). For example,
a large-scale population based survey has recently suggested
that IBD patients experience symptom relief with marijuana use
(Weiss and Friedenberg, 2015). The C. sativa plant produces
over 100 terpenophenolic molecules, i.e., the phytocannabinoids,
which accumulates predominantly in the plant glandular
trichomes (Russo, 2011). Clearly, the most known among the
phytocannabinoids is 19-tetrahydrocannabinol (THC), whose
possible clinical use is hindered by its psychoactivity. This
obstacle has addressed further research toward non-psychotropic
phytocannabinoids such as cannabidiol (CBD), the versatile
pharmacology of which is well established (Esposito et al., 2013;
Welty et al., 2014; Brodie et al., 2015; Burstein, 2015; McPartland
et al., 2015).
Among numerous pharmacological actions of potential
therapeutic interest, pure CBD has been shown to ameliorate
experimental colitis (Borrelli et al., 2009; Jamontt et al., 2010;
Schicho and Storr, 2012) and to normalize motility in the
inflamed mouse gut (Capasso et al., 2008; Lin et al., 2011). It
is worthy of note that the beneficial effects of pure CBD in the
inflamed gut have been not observed/evaluated after oral gavage
(intragastric) administration, a route of drug administration
which is easy to be translated to humans for therapeutic use. In
the past few years, the contribution of minor phytocannabinoids
to the complex Cannabis pharmacology has been shown
(Pertwee, 2008; Hill et al., 2012; McPartland and Russo, 2014)
and a number of examples of additive/synergistic effects among
the phytocannabinoids have been reported (Williamson and
Evans, 2000; Wilkinson et al., 2003; DeLong et al., 2010;
Jamontt et al., 2010; Russo, 2011; McPartland and Russo, 2014).
This observation prompted the cultivation of specific C. sativa
chemotypes (chemical genotypes) with high yields of a specific
cannabinoid (Potter, 2014). To produce a C. sativa extract, the
flowers of female plants are immersed in liquid carbon dioxide at
extremely high pressure and the chemical compounds dissolving
in this solvent are then separated and purified (Potter, 2014).
One of the best studied among such extracts is the standardized
C. sativa extract with high content of CBD, generally referred to as
CBD BDS (an acronym for Botanical Drug Substance). Notably,
CBD BDS is a major ingredient of the medicine known with
the generic name nabiximols (Sativex R©; GW Pharmaceuticals,
Cambridge, UK), approved in many countries for the treatment
of refractory spasticity in multiple sclerosis (Syed et al., 2014). In
the present study, we have examined the effect of CBD BDS in the
murine model of colitis induced by dinitrobenzenesulfonic acid.
In addition, because motility alterations represent an hallmark
in IBD patients, we also investigated the effect of the C. sativa
extract in the model of intestinal dysmotility induced by the
pro-inflammatory agent croton oil.
MATERIALS AND METHODS
Drugs and Reagents
A standardized C. sativa extract with high content in CBD (CBD
BDS, 63.9% w/w of CBD content) and pure CBD, [purity by
high-performance liquid chromatography (HPLC), 99%] were
supplied by GW Pharmaceuticals (Cambridge, UK). The dose
of CBD BDS used in the experiments refers to the amount
of CBD contained in the extract (e.g., 10 mg/kg of CBD
BDS indicates a dose of the BDS that contains 10 mg/kg of
CBD). 2,4,6-dinitrobenzenesulfonic acid (DNBS), croton oil and
myeloperoxidase (MPO) from human leucocytes, were purchased
from Sigma Aldrich S.r.l. (Milan, Italy). Pure CBD and CBD
BDS were dissolved in ethanol/Tween20/saline (1:1:8) for i.p.
injection (60 µl/mouse) or in sesame oil (90 µl/mouse) for oral
gavage administration. DNBS was solubilized in 50% ethanol
(0.15 ml/mouse). The pure CBD and CBD BDS vehicles had no
significant effects on the responses under study.
Plant Material Extraction and
Composition of the Cannabis Extract
A C. sativa chemotype with a controlled high amount of CBD
(de Meijer et al., 2003) was used for the preparation of CBD
BDS. Details about the extraction, purification as well as typical
HPLC chromatogram are reported elsewhere (Romano et al.,
2014). The composition (%, w/w) of the main phytocannabinoids
in CBD BDS was CBD 63.9 ± 5.9, 19-THC 3.0. cannabigerol
2.8, cannabichromene 3.1, cannabidivarin 1.4. The extract was
prepared in GW Pharmaceuticals laboratories (Cambridge, UK).
Animals
Male ICR mice, weighing 20–25 g for upper gastrointestinal
transit experiments and 25–30 g for colitis experiments, were
obtained from Charles River Laboratories (Calco, Lecco, Italy)
and housed in polycarbonate cages under a 12 h light/dark cycle
with light on at 07:00 a.m., controlled temperature (23 ± 2◦C)
and constant humidity (60%). Mice were fed ad libitum with
standard food, except for the 24 h period immediately preceding
the administration of DNBS, for the 12 h period preceding the
measurement of intestinal transit and for the 2 h period preceding
the oral gavage of drugs. All experiments complied with the
Italian D.L. no. 116 of 27 January 1992 and associated guidelines
in the European Communities Council Directive of 24 November
1986 (86/609/ECC). According to recent preclinical guidelines in
pharmacology, group data subjected to statistical analysis had a
minimum of n = 5 independent animals per group (Curtis et al.,
2015).
Induction of Experimental Colitis
Colitis was induced by the intracolonic administration of
DNBS as described before (Borrelli et al., 2015). Briefly, mice
were anesthetized with inhaled 5% isoflurane (Centro Agrovete
Campania, Scafati, SA, Italy) and DNBS (150 mg/kg) was injected
in the distal colon using a polyethylene catheter (1 mm in
diameter) via the rectum (4.5 cm from the anus). All animals were
sacrificed 3 days after DNBS administration by asphyxiation with
CO2, the mice abdomen was opened by a midline incision and
the colon removed, isolated from surrounding tissues, opened
along the antimesenteric border, rinsed, weighed, and length
measured [in order to determined the colon weight/colon length
ratio (mg/cm), used as an indirect marker of inflammation]. Mice
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body weight was measured every day throughout the treatment
period. All measurements were performed by operators who
were unaware of the particular treatment (blinded evaluation).
For biochemistry analysis, tissues were kept at 80◦C until use.
The dose of DNBS (150 mg/kg) and the time point of damage
evaluation (i.e., 3 days after DNBS administration) were selected
on the basis of preliminary experiments showing a remarkable
colonic damage associated with high reproducibility and low
mortality for this dosage, and because maximal DNBS-induced
inflammation has been reported in mice after 3 days (Massa et al.,
2004).
Intestinal Hypermotility Induced by
Croton Oil
Increased intestinal motility was induced by the inflammatory
agent croton oil as described before (Pol and Puig, 1997; Capasso
et al., 2008). Briefly, two doses of croton oil (20 µl/mouse) for
two consecutive days were orally administered to mice and 4 days
after the first administration of croton oil, upper gastrointestinal
transit of mice was measured. This time was selected on the
basis of previous work (Pol and Puig, 1997), which reported
that the maximal inflammatory response associated to intestinal
hypermotility occurs 4 days after the first treatment.
Upper Gastrointestinal Transit
Upper gastrointestinal transit, measured in control, and in mice
with intestinal inflammation-induced accelerated intestinal
motility (mice treated with croton oil), was evaluated by
identifying the leading front of an intragastrically administered
charcoal meal marker (10% charcoal suspension in 5%
gum Arabic, 10 ml/kg) in the small intestine as previously
described (Capasso et al., 2014). Twenty minutes after charcoal
administration, mice were killed by asphyxiation with CO2, and
the small intestine was isolated by cutting at the pyloric and
ileocaecal junctions. The distance traveled by the marker was
measured and expressed as a percentage of the total length of the
small intestine from pylorus to caecum.
Pharmacological Treatment
In the experimental model of colitis pure CBD, CBD BDS or
vehicle were given intraperitoneally (5–30 mg/kg) or by oral
gavage (10–60 mg/kg) for three consecutive days starting 24 h
after DNBS administration [Day 0: colitis induction; day 1: CBD
BDS (or CBD); day 2: CBD BDS (or CBD); day 3: CBD BDS
(or CBD) and mice sacrifice]. The last administration of CBD
BDS (or CBD) was given (at day 3) 1 h (for intraperitoneal
administration) or 2 h (for oral gavage) before the sacrifice.
In the experimental model of upper gastrointestinal transit
pure CBD, CBD BDS, or vehicle were given intraperitoneally
(1–10 mg/kg) or by oral gavage (5–60 mg/kg) 30 min
(intraperitoneally) or 1 h (oral gavage) before the administration
of the marker, to both control mice, and mice with increased
intestinal motility induced by the inflammatory agent croton oil.
The CBD BDS and pure CBD doses were selected on the basis
of previously published work (Borrelli et al., 2009; Romano et al.,
2014).
Myeloperoxidase (MPO) Activity
Myeloperoxidase activity, a peroxidase enzyme used to quantify
the neutrophil infiltration in whole-tissue colons, was determined
as previously described (Borrelli et al., 2015). Full-thickness
colons were homogenized in a lysis buffer composed of 0.5%
hexadecyltrimethylammonium bromide in 3-(N morpholino)
propanesulfonic acid (MOPS) 10 mM in the ratio of 50 mg
tissue per mL MOPS. The homogenates were then centrifuged
for 20 min at 15,000 × g at 4◦C. An aliquot of the supernatant
was incubated with sodium phosphate buffer (NaPP pH 5.5) and
tetra-methylbenzidine 16 mM. After 5 min, hydrogen peroxide
(H2O2; 9.8 M in NaPP) was added and the reaction stopped with
acetic acid. The rate of change in absorbance was measured by a
spectrophotometer at 650 nm. Different dilutions of human MPO
enzyme of known concentration were used to obtain a standard
curve. MPO activity was expressed as U/mg of tissue.
Tissue CBD Assay: Extraction,
Purification, and LC IT-TOF Mass
Spectrometry
Colon, liver, and brain samples were dounce-homogenized and
extracted with acetone containing internal deuterated standards
for CBD quantification by isotope dilution ([2H]4 CBD). The
lipid-containing organic phase was dried down, weighed, and
pre-purified by open bed chromatography on silica gel. Fractions
were obtained by eluting the column with 99:1, 90:10, and 50:50
(v/v) chloroform/methanol. The 99:1 fraction was used for CBD
quantification by LC-MS-IT-TOF analysis using an LC20AB
coupled to a hybrid IT-TOF detector (Shimadzu Corporation,
Kyoto, Japan) equipped with an ESI interface. We acquired full-
scan MSn spectra of selected precursor ions by multiple reaction
monitoring (MRM), extracted the chromatograms of the high-
resolution [M–H]− values and used the latter chromatograms for
calibration and quantification.
HPLC Parameters
Liquid chromatography analysis was performed in the isocratic
mode using a KinetexC18 column (10 cm × 2.1 mm, I.D. 5 µm,
100 A; Phenomenex) and methanol:water (75:25) with 0.1%
NH4C2H3O2 as mobile phase with a flow rate of 150 µl/min.
The samples were injected with a SIL-20 AC autosampler
(Shimadzu Corporation, Kyoto, Japan). The amounts of CBD in
tissues, quantified by isotope dilution with the abovementioned
deuterated standard, are expressed as ng per mg of tissue weight.
Mass Spectrometry Parameters
Electrosprayed ions were generated using a capillary voltage of
4.66 kV. A curved desolvation line (CDL) was set at a temperature
of 250◦C to aid desolvation and a heat block temperature of
220◦C was also used. To help nebulisation of the electrospray
solution nitrogen was pumped into the ion source at a rate of
1.5 L/min. The ToF mass analyzer was used to acquire data in
both MS and MS/MS modes. In the MS mode, a 10 ms ion
accumulation time was used before ion trapping. In the MS–
MS mode, instead, the ion accumulation time was 20 ms and
the window used for precursor ion isolation corresponds to
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a width of 3 atomic mass unit (amu) and 20 ms. To induce
fragmentation of the precursor ion a supplementary alternative
current (AC) potential was applied to the end-cap electrodes to
induce resonant excitation and argon is used as a collision gas
during collision-induced dissociation (CID). The collision was
carried out over 30 ms using a q-value of 0.251 (45 kHz). Three
scans were accumulated in each MS–MS spectrum. In both MS
and MS–MS mode data were acquired over a mass range of 200–
500 m/z. In both regimes of operation ions are pulsed into the
time of flight (ToF) with an accelerating potential of 9 kV and the
detector voltage is set at 1.7 kV (Piscitelli et al., 2011).
Full details of the quantification of CBD using LC-MS-IT-ToF-
MS will be published elsewhere (Piscitelli et al., 2011, manuscript
in preparation].
Statistical Analysis
Data are expressed as the mean ± SEM of n experiments.
To determine statistical significance, Student’s t-test was used
for comparing a single treatment mean with a control mean,
and a one-way ANOVA followed by a Tukey–Kramer multiple
comparisons test was used for analysis of multiple treatment
means. P-values< 0.05 were considered significant.
RESULTS
Effect of CBD BDS and Pure CBD on
Body Weight and Colon Weight/Colon
Length Ratio
The administration of DNBS caused both a significant decrease
in body weight and a significant increase in colon weight/length
ratio when compared to control mice (Figures 1 and 2).
Treatment of DNBS mice with CBD BDS, given intraperitoneally
at the range dose of 5–30 mg/kg, did not modify the loss of
body weight induced by the inflammatory agent (Figure 1A) but
reduced DNBS-increased colon weight/length ratio (Figure 1B).
The effect was significant at the 30 mg/kg dose (Figure 1B).
Likewise, oral gavage administration of CBD BDS (10–60 mg/kg)
FIGURE 1 | Effect of CBD BDS (5–30 mg/kg, intraperitoneally) on body weight (A) and colon weight/colon length ratio (B) and effect of CBD BDS
(10–60 mg/kg, oral gavage) on body weight (C) and colon weight/colon length ratio (D) in DNBS induced colitis in mice (DNBS, 150 mg/kg,
intracolonically). CBD BDS was given once a day for three consecutive days starting from 1 day after DNBS administration. Mice were euthanized 3 days after
DNBS. Mice were weighted before DNBS (or vehicle) administration and immediately before the sacrifice. Bars are mean ± SEM of 8–12 mice for each experimental
group. #p < 0.001 vs. control and ∗p < 0.05 vs. DNBS alone.
Frontiers in Pharmacology | www.frontiersin.org 4 October 2016 | Volume 7 | Article 341
fphar-07-00341 September 30, 2016 Time: 17:24 # 5
Pagano et al. Cannabis Extract and Intestinal Inflammation
FIGURE 2 | Effect of pure CBD (5–30 mg/kg, intraperitoneally) on body weight (A) and colon weight/colon length ratio (B) and effect of pure CBD
(10–60 mg/kg, by oral gavage) on body weight (C) and colon weight/colon length ratio (D) in DNBS induced colitis in mice (DNBS, 150 mg/kg,
intracolonically). Pure CBD was given once a day for three consecutive days starting from 1 day after DNBS administration. Mice were euthanized 3 days after
DNBS. Mice were weighted before DNBS (or vehicle) administration and immediately before the sacrifice. Bars are mean ± SEM of 8–12 mice for each experimental
group. #p < 0.001 vs. control.
had no effect on the DNBS-induced decrease in body weight,
although a trend in reducing weight loss was observed at the
60 mg/kg dose (Figure 1C). CBD BDS, given via oral gavage at
the 60 mg/kg dose, significantly reduced the colon weight/length
ratio increased by DNBS (Figure 1D).
Pure CBD, when both given intraperitoneally (5–30 mg/kg) or
by oral gavage (10–60 mg/kg), did not ameliorate DNBS-induced
colitis (no variation on body weight and colon weight/colon
length ratio; Figure 2).
Effect of CBD BDS on MPO Activity
The beneficial effect of CBD BDS on DNBS-induced colitis was
further confirmed by the MPO results. DNBS administration
produced a threefold increase in MPO activity which was
significantly reduced by either intraperitoneal or oral gavage
administration of CBD BDS at the 30 mg/kg and 60 mg/kg dose,
respectively (Figure 3).
Effect of Pure CBD and CBD BDS on
Upper Gastrointestinal Transit
CBD BDS, given intraperitoneally at the dosage range of
1–10 mg/kg, reduced the intestinal transit in healthy mice,
the effect being significant only at the higher dose tested
(10 mg/kg; Figure 4A). CBD BDS (1–10 mg/kg), in a dose
dependent manner, counteracted the increase in intestinal
motility induced by croton oil (Figure 4B). The effect was
significant starting from the 1 mg/kg dose. Analysis of the
curves representing the inhibitory effect of CBD BDS on transit
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FIGURE 3 | Inhibitory effect of CBD BDS 30 mg/kg, intraperitoneally (A)
and CBD BDS 60 mg/kg, by oral gavage (B) on myeloperoxidase (MPO)
activity in DNBS induced colitis in mice (DNBS, 150 mg/kg,
intracolonically). MPO activity was measured on colonic tissues 3 days after
vehicle or DNBS administration. CBD BDS was given once a day for three
consecutive days starting from 1 day after DNBS administration. Mice were
euthanized 3 days after DNBS. Bars are mean ± SEM of 4–5 mice for each
experimental group. #p < 0.001 vs. control and ∗p < 0.05 ∗∗p < 0.01 vs.
DNBS alone.
in healthy mice and in mice with hypermotility induced by
croton oil shows that CBD BDS preferentially inhibited intestinal
transit in pathophysiological rather than physiological conditions
(Figure 4). Likewise, CBD BDS when given by oral gavage at
the dosage range of 5–60 mg/kg reduced the intestinal transit
in healthy mice, the effect being significant starting from the
10 mg/kg dose (Figure 5A). Similar to the intraperitoneal
administration, oral gavage administration of CBD BDS (5–
60 mg/kg), in a dose dependent manner, reduced the intestinal
hypermotility induced by croton oil (Figure 5B). The effect
was significant starting from the 5 mg/kg dose. Analysis of the
curves representing the inhibitory effect of CBD BDS on transit
in healthy mice and in mice with hypermotility induced by
croton oil shows that CBD BDS, also when given by oral gavage,
preferentially inhibited intestinal transit in pathophysiological
rather than physiological conditions (Figure 5).
As previously reported (Capasso et al., 2008), pure CBD,
given intraperitoneally at the dose range of 1–10 mg/kg, did
not affect the intestinal transit in healthy mice (Figure 6A)
but, significantly and in a dose dependent manner, restored the
intestinal motility in mice with hypermotility induced by croton
oil (Figure 6B). The effect was significant starting from the
5 mg/kg dose (Figure 6B). Oral gavage administration of pure
CBD did not reduce intestinal transit in healthy mice (Figure 6C),
and reduced the croton oil-induced accelerated intestinal motility
at the 5 mg/kg dose only (Figure 6D).
CBD Levels in Tissues of Mice with
DNBS-Induced Inflammation after Oral
Treatment with Pure CBD or CBD BDS
As shown in Figure 7, CBD was detected in the colon, liver,
and brain in mice treated with either CBD BDS or pure CBD
(oral administration). In the colon (Figure 7A) and in the brain
(Figure 7B), the content increased with the dose in the case of
pure CBD, while in the CBD BDS group there were no differences
between the two doses.
In the liver, CBD tissue penetration was higher with the
oral administration of CBD-BDS, in a dose-dependent manner
(Figure 7C), while there were no significant differences between
pure CBD at 30 and 60 mg. Interestingly, higher CBD levels were
achieved with pure CBD in the colon and brain, and much higher
CBD levels were achieved with CBD BDS in the liver.
DISCUSSION
The notion that not all of the therapeutic effects of C. sativa
are due to its many active psychotropic ingredient THC is
well established (Wilkinson et al., 2003; Russo, 2011; Brodie
et al., 2015). The contribution of non-THC phytocannabinoids
to Cannabis pharmacology has been scientifically demonstrated
in a number of experimental diseases, including ulcerative colitis
(Duncan and Izzo, 2015). In previous studies, it has been shown
that isolated Cannabis constituents, including cannabichromene
(CBC), CBD and cannabigerol (CBG), exert favorable effects in
experimental models of IBD (Borrelli et al., 2009, 2013; Jamontt
et al., 2010; Romano et al., 2013). In the present study, we have
expanded our knowledge on the intestinal anti-inflammatory
effect of phytocannabinoids by showing for the first time that
a Cannabis extract with high content in CBD, namely CBD
BDS, when both given intraperitoneally and by oral gavage,
is able to reduce the extent of the damage and to counteract
intestinal hypermotility in experimental models of intestinal
inflammation. By contrast, we demonstrated that pure CBD,
either given intraperitoneally or by oral gavage at matched CBD
doses with CBD BDS, after the inflammatory insult does not offer
anti-inflammatory effects.
The route of administration for cannabinoids is a major
issue since cannabinoids are significantly metabolized by hepatic
cytochrome enzymes (Huestis, 2005). There is no evidence
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FIGURE 4 | Effect of CBD BDS (1–10 mg/kg, intraperitoneally) on intestinal transit in healthy mice (A) and croton oil-treated mice (B). Bars represent the
mean ± SEM of 8–10 animals for each experimental group. ◦ and #p < 0.05, ◦◦p < 0.01, and ◦◦◦p < 0.001 vs. control and ∗p < 0.05 and ∗∗∗p < 0.001 vs. croton
oil alone. Insert: Difference between the curves representing the inhibitory effect of CBD BDS on intestinal transit in healthy mice and mice with hypermotility (mice
treated with croton oil). Results are expressed as mean ± SEM of 8–10 mice for each experimental group. ∗∗∗p < 0.001 vs. healthy mice.
in the literature that cannabinoids may exert intestinal anti-
inflammatory effects when given orally. While the intraperitoneal
route of administration is extensively used in rodent experiments,
it appears clear that such a way of delivery is hard to be
translated to humans. In the present study, we have shown that
CBD BDS, given intraperitoneally or by oral gavage, reduces
inflammation associated to DNBS administration. Although we
did not provide a microscopic score, as done for CBD in our
previous work (Borrelli et al., 2009), the anti-inflammatory
effect of CBD BDS was supported by colon length/weight ratio
and by the MPO measurements, two well-established marker
of intestinal inflammation (Krawisz et al., 1984; Kristjánsson
et al., 2004). In addition, CBD BDS (intraperitoneally or
orally) was pharmacologically active when administered after the
inflammatory insult, which is clinically relevant in the light of
the observation that the main goal of IBD pharmacotherapy is
to cure rather than to prevent. In previous studies aimed at
investigating the intestinal anti-inflammatory effects of Cannabis
and its active ingredients, phytocannabinoids, including CBD,
were given before the inflammatory insult (i.e., preventive
protocol) (Borrelli et al., 2009; Jamontt et al., 2010; Schicho and
Storr, 2012). In contrast to CBD BDS, pure CBD does not exert
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FIGURE 5 | Effect of CBD BDS (10–60 mg/kg, by oral gavage) on intestinal transit in healthy mice (A) and croton oil-treated mice (B). Bars represent the
mean ± SEM of 8–10 animals for each experimental group. ◦ and #p < 0.05, ◦◦p < 0.01 and ◦◦◦p < 0.001 vs. control and ∗∗p < 0.01 and ∗∗∗p < 0.001 vs. croton
oil alone. Insert: Difference between the curves representing the inhibitory effect of CBD BDS on intestinal transit in healthy mice and mice with hypermotility (mice
treated with croton oil). Results are expressed as mean ± SEM of 8–10 mice for each experimental group. ∗∗∗p < 0.001 vs. healthy mice.
anti-inflammatory effects either when given intraperitoneally or
by oral gavage even with the high doses. The lack of effect of pure
CBD (up to 20 mg/kg) after oral gavage, but not after intracolonic,
administration has been previous documented (Schicho and
Storr, 2012) and may be not surprising if we consider that this
type of administration is subjected to a significant first-pass effect
(Huestis, 2005).
The difference in efficacy between pure CBD and CBD
BDS is likely due to the presence of pharmacologically active
ingredients. Indeed, in addition to CBD, CBD BDS contains
other phytocannabinoids, such as THC, CBC, and CBG, which
have been previously shown to exert anti-inflammatory effects in
experimental models of colitis (Jamontt et al., 2010; Borrelli et al.,
2013; Romano et al., 2013) and whose colonic levels were not
determined in the present study. Furthermore non-cannabinoid
C. sativa constituents, such as flavonoids, phytosterols, and
terpenoids, have been shown to ameliorate murine colitis (Reddy,
1976; Somani et al., 2015; Vezza et al., 2016). On the other
hand, the higher efficacy of oral CBD BDS does not seem to be
ascribable to higher penetration of CBD in the colon when using
this drug. In fact, we show here that the exposure to CBD of both
the colon and brain after oral administration of either pure CBD
or CBD BDS is higher with the highest dose of pure CBD than
with the highest dose of CBD BDS, and similar with the lowest
doses of the two drugs. Conversely, in the liver, the concentration
of CBD, at both doses tested, was higher with CBD BDS than with
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FIGURE 6 | Effect of intraperitoneal administration of pure CBD (1–10 mg/kg) on intestinal transit in healthy mice (A) and croton oil-treated mice (B),
and oral gavage administration of pure CBD (5–60 mg/kg) on intestinal transit in healthy mice (C) and croton oil-treated mice (D). Bars represent the
mean ± SEM of 8–10 animals for each experimental group. #p < 0.05–0.01 vs. control; ∗p < 0.05 and ∗∗p < 0.01 vs. croton oil alone.
pure CBD. Interestingly, the maximal colonic concentrations of
CBD at the end of treatment can be calculated to be ∼30 nM
with CBD BDS and ∼100 nM with pure CBD, which are not
too distant from the potencies of this compound at many of
its proposed molecular targets (McPartland and Russo, 2014;
Brodie et al., 2015). Others have shown that a non-chemically
characterized Cannabis extract reduced the severity of rat colitis
when administered intracolonically (Wallace et al., 2013).
Inflammatory states in the gut may cause motility
disturbances, and alterations in intestinal motility are common
debilitating symptoms (Brierley and Linden, 2014). To
investigate the effect of CBD BDS on intestinal motility, we
adopted the croton oil model of intestinal inflammation-induced
hypermotility. This model has been extensively used in the past
to evaluate the potential of drugs able to reduce intestinal motility
such as opioids (Pol and Puig, 2004) and cannabinoids (Aviello
et al., 2008). By using this experimental model, it has been shown
that a number of phytocannabinoids, including CBD, CBC, and
CBN (Izzo et al., 2000, 2012; Capasso et al., 2008), normalize
motility during the inflammatory process, with weak or no effect
in control mice. In the present study, we have shown that both
CBD BDS and pure CBD, given intraperitoneally or by oral
gavage, reduce motility in mice with intestinal inflammation,
with weak (CBD BDS) or no (pure CBD) effects in control mice.
From a translational viewpoint, the low doses of CBD BDS
(and pure CBD) required to normalize motility in the inflamed
gut – as well as their pharmacological activity following oral
gavage administration – are relevant if we consider that the
drugs available to reduce motility may be often associated with
constipation (Corsetti and Tack, 2015; Rao et al., 2016).
The anti-inflammatory mode of action of CBD BDS in the
gut is still elusive and deserves further ad hoc studies. CBD
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FIGURE 7 | CBD levels in colon (A), brain (B), and liver (C) of DNBS-treated mice after oral administration of either CBD BDS or CBD. Data are
means ± SEM of N = 5–6 mice.
and other minor phytocannabinoids contained in CBD BDS
may interact with targets (e.g., components of the so-called
endogenous cannabinoid system, TRP channels; De Petrocellis
et al., 2011, 2012) which have been linked to IBD (Izzo et al.,
2015; Zielin´ska et al., 2015). Recently, pharmacological blockade
of GPR55 has been shown to protect against experimental gut
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inflammation (Stancˇic´ et al., 2015), a relevant finding in the light
of the observation that CBD is a GPR55 antagonist (Ryberg et al.,
2007; Campos et al., 2012). Conversely, the antioxidant effect is
believed to not entirely explain per se the gut anti-inflammatory
actions exerted by CBD (Esposito et al., 2013).
CONCLUSION
The present study reveals for the first time the ability of the
CBD BDS to attenuate the severity of inflammation in the DNBS
model of colitis, as well as to reduce transit in a model of
inflammation-induced dysmotility. The strengths of CBD BDS
for a possible clinical use in IBD patients include: (a) its intestinal
anti-inflammatory activity following oral gavage administration
(in contrast to pure CBD, which was ineffective); (b) its ability
to reduce the degree of inflammation in a curative protocol, (c)
its ability to reduce motility in the inflamed gut at doses lower
than those required to affect motility in control animals. Our
results further support the therapeutic rationale for combining
CBD with other minor constituents present in Cannabis sativa,
also in the light of recent positive effects exerted by CBD
BDS (also named GWP42003) in IBD patients (Irving et al.,
2015).
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